SOUTH SAN FRANCISCO (dpa-AFX) - Swiss drug major Roche Group (RHHBY) announced Monday the global availability of blood-based genomic profiling test, FoundationOne Liquid.
FoundationOne Liquid, a liquid biopsy test, can identify circulating tumour DNA in the blood of people living with cancer and can identify 70 of the most commonly mutated genes in solid tumours. This includes microsatellite instability, a genomic signature which may help inform cancer immunotherapy based treatment decisions.
From a single blood sample, the liquid biopsy offers a quick and convenient option for some patients with solid tumours.
FoundationOne Liquid complements FoundationOne CDx, a tissue-based genomic profiling test launched in the US earlier this year, to deliver a portfolio of comprehensive genomic profiling services for healthcare professionals.
The blood sample is sent to a Foundation Medicine lab where the test is performed using next generation sequencing to analyse the four main classes of genomic alterations as well as microsatellite instability, an indicator that may help inform immunotherapy treatment decisions using ctDNA isolated from plasma derived from peripheral whole blood.
Copyright RTT News/dpa-AFX